Post by Irina Meln, PhD

🚀 From stakeholder dialogue to regulatory impact At the European Vaccine Initiative (EVI), I value most the opportunity to translate #stakeholderengagement into tangible progress for #globalhealth 🌍 As part of the #Inno4Vac project, I had the privilege to organise a #regulatory workshop bringing together regulators (from seven agencies!), industry, academia, and global health partners to discuss the role of in silico models in accelerating #vaccine #development and regulatory decision-making 🤝 The outcomes of this exchange have now been published in Vaccine, reflecting shared perspectives and actionable recommendations for advancing the integration of modelling approaches in vaccine R&D and regulation: 👉 https://lnkd.in/eMayNWug This publication highlights how structured, cross-sector #collaboration can directly inform #regulatory science and support #innovation pathways in vaccine development. My sincere thanks to all internal and external collaborators for their valuable contributions, and to the Innovative Health Initiative (IHI) for funding and enabling this work 💙 Wim Van Molle and Koen Brusselmans (Sciensano); Mónica Perea-Vélez and Antonio Gaetano Cardillo (GSK), Marc Baay (P95), Dan Bracewell (UCL), Didier Clenet, Léa Girardon, Noémie Mansois (Sanofi), Caroline Forestieri and Pierre Lebrun, Natalis Laurent (PharmaLex), Arnar Gudjonsson (Norwegian Medical Products Agency), Antonio G. and Renske Hesselink (CEPI (Coalition for Epidemic Preparedness Innovations), John Bagterp Jørgensen (2-control ApS), Hannah Lanzrath and Eric von Lieres (Forschungszentrum Jülich), Xiyan Li Li (DTU - Technical University of Denmark); Julius P. (Paul-Ehrlich-Institut); Sevda Senel (Hacettepe University Faculty of Pharmacy); Martin Spruth (Austrian Agency for Health and Food Safety), Mats Welin (Medical Products Agency Läkemedelsverket) #GlobalHealth #Vaccines #RegulatoryScience #Innovation #Inno4Vac #PublicHealth